<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, Jan. 29, 2020 (HealthDay News) — A nationalized kidney paired donation program results in equivalent outcomes compared with control living kidney donor transplant, according to a study published online Jan. 28 in the Clinical Journal of the American Society of Nephrology<\/i>.<\/p>\n
David B. Leeser, M.D., from East Carolina University in Greenville, North Carolina, and colleagues estimated the risk for death-censored graft failure and mortality among 2,363 National Kidney Registry recipients and 54,497 control kidney transplant recipients.<\/p>\n
The researchers found that National Kidney Registry recipients were more likely to be female, African-American, older, and on public insurance. They were also more likely to have a panel of reactive antibodies >80, spend longer on dialysis, and be a previous transplant recipient. During a median follow-up of 3.7 years for National Kidney Registry recipients, they had similar graft failure (5 versus 6 percent; log-rank P = 0.2) and mortality incidence (9 versus 10 percent; log-rank P = 0.4) compared with controls. No detectable difference was seen between National Kidney Registry and control recipients in graft failure (adjusted hazard ratio, 0.95; 95 percent confidence interval, 0.77 to 1.18; P = 0.6) or mortality (adjusted hazard ratio, 0.86; 95 percent confidence interval, 0.70 to 1.07; P = 0.2) after adjustment for donor, recipient, and transplant factors.<\/p>\n
“These results should reassure the larger transplant community that a national kidney paired donation program is a safe and effective way to treat patients with incompatible living donors,” the authors write.<\/p>\n
One author disclosed financial ties to Sanofi, Novartis, and CSL Behring.<\/p>\n
Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n Editorial (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n